Tazemetostat

December 17, 2019December 20, 2019

Meeting with FDA Supports Tazemetostat for Some Follicular Lymphoma

News

Epizyme successfully met with the U.S. Food and Drug Administration (FDA) to bolster an upcoming submission of its oral investigational treatment tazemetostat for relapsed or resistant follicular lymphoma, with or ... Read more

January 11, 2019

Epizyme Planning to Request FDA’s Accelerated Approval of Tazemetostat for Follicular Lymphoma Patients

News

Epizyme plans to ask the U.S. Food and Drug Administration (FDA) for accelerated approval of tazemetostat as a treatment for people with relapsed or refractory follicular lymphoma with or without EZH2 activating mutations. ... Read more

April 27, 2018April 27, 2018

FDA Orders Enrollment Hold on Tazemetostat Clinical Trials

News

Patient enrollment for clinical trials of Epizyme’s tazemetostat is temporarily on hold. The decision from the U.S. Food and Drug Administration (FDA) follows a safety report of a pediatric patient ... Read more

April 23, 2018

Some Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma Patients Respond Well to Tazemetostat in Phase 1 Trial

News

The investigational EZH2 inhibitor tazemetostat was safe and shrank tumors in 38 percent of patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma who were included in the first part of a ... Read more

June 28, 2017June 28, 2017

Tazemetostat Benefits Follicular and B-cell Lymphoma Patients with EZH2 Mutations, Phase 2 Trial Shows

News

Twelve of 13 patients with relapsed or refractory follicular lymphoma (FL) and mutations of the EZH2 enzyme responded either fully or partially to treatment with tazemetostat, according to a Phase 2 clinical trial. Tazemetostat, ... Read more

May 1, 2017May 1, 2017

Epizyme’s Tazemetostat Receives FDA Fast Track Designation to Treat Follicular Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted Fast Track status to Epizyme‘s tazemetostat as a potential treatment for relapsed or refractory follicular lymphoma patients with or without EZH2 activating mutations, ... Read more

February 8, 2017

Strata to Help Epizyme Find Patients for Non-Hodgkin Lymphoma Trial of Tazemetostat

News

Strata Oncology will help Epizyme accelerate patient enrollment in the Phase 2 clinical trial assessing Epizyme’s EZH2 inhibitor tazemetostat in patients with relapsed or refractory non-Hodgkin lymphoma. Strata is conducting ... Read more

June 22, 2016June 22, 2016

Epizyme Presents Positive Clinical Data on Tazemetostat in Relapsed or Refractory Non-Hodgkin’s Lymphoma

News

Epizyme announced new and positive data from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of orally administered tazemetostat in relapsed or refractory patients with non-Hodgkin’s lymphoma. The ... Read more

May 16, 2016May 16, 2016

Epizyme to Present Clinical Data on NHL Treatment at ASH Lymphoma Conference

News

Epizyme, Inc., recently announced it will present four abstracts at the upcoming American Society of Hematology (ASH) Conference on Lymphoma Biology. The abstracts report data from its clinical development program of tazemetostat in patients ... Read more

May 10, 2016May 10, 2016

Epizyme and LYSA Open Clinical Trial of Combo Therapy for Diffuse Large B-Cell Lymphoma

News

Epizyme, Inc., and the Lymphoma Study Association (LYSA) will jointly investigate the combination of tazemetostat and R-CHOP as a frontline treatment in patients with diffuse large B-cell lymphoma (DLBCL), the most common ... Read more